Obesity and Cancer: Optimizing Risk Assessment Edward R. Sauter ASO Perspectives 30 October 2022 Pages: 653 - 657
How Biomarkers of Response to Chemotherapy Might Change Patient Management William G. HawkinsChet W. HammillSamuel J. Ballentine ASO Perspectives 23 November 2022 Pages: 658 - 659
Optimizing Treatment Strategies with Preoperative Assessment for Microvascular Invasion in Hepatocellular Carcinoma Daniel W. NelsonJean-Nicolas Vauthey Hepatobiliary Tumors 30 October 2022 Pages: 660 - 662
Routine Omentectomy During Cytoreductive Surgery for Peritoneal Surface Malignancies Stephanie YoungJingjing YuMaheswari Senthil Peritoneal Surface Malignancy 07 December 2022 Pages: 663 - 664
Does Surgery Need to be Reserved for Patients with Residual Disease After Radiochemotherapy for Proximal Squamous Cell Carcinoma? Caroline Gronnier Thoracic Oncology 23 November 2022 Pages: 665 - 666
Commentary: The Role of PET Scan Uptake in Determining Prognosis in Early-Stage Lung Cancer Audrey C. Pendleton Thoracic Oncology 28 November 2022 Pages: 667 - 668
Dual Image Navigation Aiding Segmentectomy for Early NSCLC: Feasible, but Useful? James TankelJonathan Cools-Lartigue Thoracic Oncology 15 November 2022 Pages: 669 - 671
Reappraisal of Robotic Assistance in Gynecologic Oncology: The Lessons of ROBOGYN-1004 Denis QuerleuGiovanni ScambiaAgnieszka Rychlik Gynecologic Oncology 15 September 2022 Pages: 672 - 674
Radiotherapy in Retroperitoneal Liposarcoma: Are We Looking for an Answer in the Wrong Place? Dario CallegaroAlessandro Gronchi Sarcoma 26 October 2022 Pages: 675 - 677
Homologous Recombination Deficiency in Triple-Negative Breast Cancer: Potential Benefit of a New Target Seigo Nakamura Breast Oncology 18 November 2022 Pages: 678 - 679
Mitotane With or Without Cisplatin and Etoposide for Patients with a High Risk of Recurrence in Stages 1–3 Adrenocortical Cancer After Surgery Amber Leila SarvestaniStephanie N. GregoryMouhammed Amir Habra ASO Research Letter 28 October 2022 Pages: 680 - 682
A Randomized Trial of Pembrolizumab & Radiotherapy Versus Radiotherapy in High-Risk Soft Tissue Sarcoma of the Extremity (SU2C-SARC032) Areeba SaifEmily A. VerbusDavid G. Kirsch ASO Research Letter 17 November 2022 Pages: 683 - 685
Durvalumab and Tremelimumab for Hepatocellular Carcinoma in Patients Listed for a Liver Transplant Carrie E. RyanJacob LambdinDavendra Sohal ASO Research Letter 18 November 2022 Pages: 686 - 687
A Randomized, Phase II, Clinical Trial of Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable, Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma Areeba SaifEmily VerbusWilliam A. Hall ASO Research Letter 24 November 2022 Pages: 688 - 690
Impact of Surgical Delays During the Initial Surge of the COVID-19 Pandemic on Patients with Breast Disease K. NicholsonK. KuchtaKatharine Yao Aso Research Letter 09 December 2022 Pages: 691 - 693
Patient-Reported Symptom Burden After Cancer Surgery in Older Adults: A Population-Level Analysis Julie HalletJesse Zuckermanand for the REcovery after Surgical Therapy for Older Adults Research-Cancer (RESTORE-C) Group Global Health Services Research 06 September 2022 Pages: 694 - 708
ASO Author Reflections: Understanding and Integrating Postoperative Patient-Reported Symptom Burden for Older Adults Undergoing Cancer Surgery Julie HalletNatalie CoburnAntoine Eskander ASO Author Reflections 06 September 2022 Pages: 709 - 710
Risk Factors and In-Hospital Outcomes of Perioperative Atrial Fibrillation for Patients with Cancer: A Meta-Analysis Keiko InoueKazuko TajiriMasaki Ieda Global Health Services Research 22 October 2022 Pages: 711 - 721
ASO Author Reflections: Perioperative Atrial Fibrillation in Patients Undergoing Cancer Surgery Kazuko TajiriKeiko Inoue ASO Author Reflections 28 October 2022 Pages: 722 - 722
ASO Visual Abstract: Risk Factors and In-Hospital Outcomes of Perioperative Atrial Fibrillation in Patients with Cancer: A Meta-analysis Keiko InoueKazuko TajiriMasaki Ieda ASO Visual Abstract 17 November 2022 Pages: 723 - 724
A Novel Online Calculator to Predict Risk of Microvascular Invasion in the Preoperative Setting for Hepatocellular Carcinoma Patients Undergoing Curative-Intent Surgery Yutaka EndoLaura AlaimoTimothy M. Pawlik Hepatobiliary Tumors 14 September 2022 Pages: 725 - 733
ASO Author Reflections: An Online Calculator to Predict Risk of Microvascular Invasion in the Preoperative Setting for Patients with Hepatocellular Carcinoma Yutaka EndoZorays MoazzamTimothy M. Pawlik ASO Author Reflections 04 September 2022 Pages: 734 - 735
ASO Visual Abstract: A Novel Online Calculator to Predict Risk of Microvascular Invasion in the Preoperative Setting for HCC Patients Undergoing Curative-Intent Surgery Yutaka EndoLaura AlaimoTimothy M. Pawlik ASO Visual Abstract 12 September 2022 Pages: 736 - 737
Impact of Social Determinants of Health on Outcomes Following Resection for Hepatocellular Carcinoma Ambria S. MotenPaxton V. DicksonEvan S. Glazer Hepatobiliary Tumors 01 November 2022 Pages: 738 - 747
ASO Visual Abstract: The Impact of Social Determinants of Health on Outcomes After Resection for Hepatocellular Carcinoma Ambria S. MotenPaxton V. DicksonEvan S. Glazer ASO Visual Abstract 23 November 2022 Pages: 748 - 749
Variations in Textbook Oncologic Outcomes After Curative-Intent Resection: Early Versus Intermediate Hepatocellular Carcinoma Based on Barcelona Clinic Liver Cancer Criteria and Child-Pugh Classification Zorays MoazzamLaura AlaimoTimothy M. Pawlik Hepatobiliary Tumors 20 November 2022 Pages: 750 - 759
ASO Author Reflections: The Barcelona Clinic Liver Cancer Criteria and Child–Pugh Classification Determine Short-Term Outcomes in Hepatocellular Carcinoma Zorays MoazzamLaura AlaimoTimothy M. Pawlik ASO Author Reflections 20 November 2022 Pages: 760 - 761
ASO Visual Abstract: Variations in Textbook Oncologic Outcomes following Curative-Intent Resection: Early versus Intermediate Hepatocellular Carcinoma Based on Barcelona Clinic Liver Cancer Criteria and Child–Pugh Classification Zorays MoazzamLaura AlaimoTimothy M. Pawlik Aso Visual Abstract 08 December 2022 Pages: 762 - 763
Extreme In Situ Liver Surgery Under Total Vascular Exclusion with Right Hepatic Vein and Inferior Vena Cava Grafts for an Intrahepatic Cholangiocarcinoma Victor Lopez-LopezPaula Gomez VallesRicardo Robles-Campos Hepatobiliary Tumors Open access 03 December 2022 Pages: 764 - 765
ASO Author Reflections: Extreme Liver Surgery for Intrahepatic Cholangiocarcinoma: To be or Not to be Resected, that is the Question Victor Lopez-LopezRicardo Robles-Campos Aso Author Reflections 07 December 2022 Pages: 766 - 767
Is Routine Omentectomy a Necessary Component of Cytoreductive Surgery and HIPEC? Sohini KhanNguyen-Huong DoanJoel Baumgartner Peritoneal Surface Malignancy Open access 28 October 2022 Pages: 768 - 773
ASO Author Reflections: Routine Omentectomy During Cytoreductive Surgery and HIPEC Sohini KhanJoel M. Baumgartner ASO Author Reflections Open access 11 November 2022 Pages: 774 - 775
ASO Visual Abstract: Is Routine Omentectomy a Necessary Component of Cytoreductive Surgery and HIPEC? Sohini KhanNguyen-Huong DoanJoel Baumgartner ASO Visual Abstract 11 November 2022 Pages: 776 - 776
Randomized Controlled Trial Investigating Perioperative Immunonutrition for Patients Undergoing Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Grace Hwei Ching TanClaramae Shulyn ChiaMelissa Ching Ching Teo Peritoneal Surface Malignancy 30 September 2022 Pages: 777 - 789
ASO Visual Abstract: A Randomized Controlled Trial Investigating Perioperative Immunonutrition for Patients Undergoing Cytoreductive Surgery (CRS) and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Grace Hwei Ching TanJolene Si Min WongMelissa Ching Ching Teo ASO Visual Abstract 17 November 2022 Pages: 790 - 791
RAS Mutation Status Should Not Be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases Dilraj BhullarSarah O’DwyerOmer Aziz Peritoneal Surface Malignancy Open access 18 November 2022 Pages: 792 - 801
ASO Visual Abstract: RAS Mutation Status Should not be Used to Predict Outcome from Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Colorectal Peritoneal Metastases Dilraj BhullarSarah O’DwyerOmer Aziz ASO Visual Abstract 20 November 2022 Pages: 802 - 803
A Multicenter Phase 1 Trial Evaluating Nanoliposomal Irinotecan for Heated Intraperitoneal Chemotherapy Combined with Cytoreductive Surgery for Patients with Peritoneal Surface Disease Minsig ChoiMegan M. HarperJoseph Kim Peritoneal Surface Malignancy 07 November 2022 Pages: 804 - 813
ASO Visual Abstract: A Multicenter, Phase 1, Trial Evaluating Nanoliposomal Irinotecan for Heated Intraperitoneal Chemotherapy Combined with Cytoreductive Surgery in Patients with Peritoneal Surface Disease Minsig ChoiMegan M. HarperJoseph Kim ASO Visual Abstract 09 December 2022 Pages: 814 - 815
Outcomes of a Phase II Study of Intraperitoneal Paclitaxel Plus Systemic Capecitabine and Oxaliplatin (XELOX) for Gastric Cancer with Peritoneal Metastases Antoine MarianiAziz ZaananMehdi Karoui Peritoneal Surface Malignancy 16 November 2022 Pages: 816 - 817
Treatment and Outcomes of Proximal Esophageal Squamous Cell Carcinoma Deven C. PatelChi-Fu Jeffrey YangMark F. Berry Thoracic Oncology 28 October 2022 Pages: 818 - 827
ASO Author Reflections: Optimizing Proximal Esophageal Squamous Cell Carcinoma Treatment Deven C. PatelMark F. Berry ASO Author Reflections 18 October 2022 Pages: 828 - 829
Prognostic Significance of the Maximum Standardized Uptake Value on the Prognosis of Clinical Stage IA Lung Adenocarcinoma Based on the 8th Edition TNM Classification Shunsuke ShigefukuHiroyuki ItoNorihiko Ikeda Thoracic Oncology 25 October 2022 Pages: 830 - 838
ASO Author Reflections: Is SUVmax Comparable with TNM Classification 8th Edition in Early-Stage Lung Adenocarcinoma? Shunsuke Shigefuku ASO Author Reflections 22 October 2022 Pages: 839 - 840
ASO Visual Abstract: Prognostic Significance of the Maximum Standardized Uptake Value on the Prognosis of Clinical Stage IA Lung Adenocarcinoma Based on the 8th Edition TNM Classification Shunsuke ShigefukuHiroyuki ItoNorihiko Ikeda ASO Visual Abstract 14 November 2022 Pages: 841 - 842
Dual Image Navigation to Secure Surgical Margins in Thoracoscopic Segmentectomy Sung Soo ChangHiroyasu YokomiseTetsuhiko Go Thoracic Oncology 02 October 2022 Pages: 843 - 849
ASO Visual Abstract: Dual Image Navigation to Secure Surgical Margins in Thoracoscopic Segmentectomy Sung Soo ChangHiroyasu YokomiseTetsuhiko Go ASO Visual Abstract 08 November 2022 Pages: 850 - 850
Long-Term Prognosis and Prognostic Indicators of Stage IA Lung Adenocarcinoma Masaya YotsukuraYuji MuraokaShun-ichi Watanabe Thoracic Oncology 19 October 2022 Pages: 851 - 858
ASO Visual Abstract: Long-Term Prognosis and Prognostic Indicators of Stage IA Lung Adenocarcinoma Masaya YotsukuraYuji MuraokaShun-ichi Watanabe ASO Visual Abstract 06 December 2022 Pages: 859 - 860
Docetaxel, Cisplatin, and 5-FU Triplet Therapy as Conversion Therapy for Locoregionally Advanced Unresectable Esophageal Squamous Cell Carcinoma Wing-Lok ChanCheuk-Wai ChoiSimon Law Thoracic Oncology 28 October 2022 Pages: 861 - 870